CREBBP and plasma cell myeloma: Treatment of myeloma cells with a potent and selective inhibitor of EP300/CBP, CCS1477 (inobrodib), evicted EP300/CBP from the enhancers of genes, inducing differentiation (Picaud et al. 2015).